Providing building blocks for controlled protein release, the inspired use of PODS is enabling research breakthroughs across biomedical science.
Poor survival of implanted retinal cells has held back therapeutic development. Sustained neurotrophic growth factor release is pushing the field forwards
Sustained release PODS-TGF-B2 enabled powerful modelling of trabecular meshwork,
Growth factors are critical controllers of cell behaviour. By providing printability and sustained release, PODS are increasing our ability to harness these key molecules in cell culture and cell therapy
Protein gradients, especially of cytokines and chemokines, are essential in biology for guiding cell migration, activating immunity, and orchestrating development. Traditional methods often struggle with unstable delivery, burst release, or limited spatial control. Here, we review common approaches and highlight the befits of PODS as a powerful, next-generation tool for engineering reliable protein gradients.
Researchers in Tokyo have leveraged PODS protein crystals to create a gold-harvesting technology that is environmentally friendly and more selective than most synthetic materials.
A new study led by researchers at the University of Glasgow presents compelling evidence of PODS ability to elevate organoid-based therapies to a new level.
Despite its promise and success in treating otherwise resistant blood cancers, CAR-T therapy comes with a hefty price tag, often exceeding hundreds of thousands of dollars per patient. Understanding why CAR-T therapy is so expensive requires a closer look at the complex processes and factors involved in its development and administration.
Immune cell reprogramming is widely used to enhance immune cell function for disease treatment. This approach is successful for some types of immune cell, such as T-cells, but reprogramming of monocytes, macrophages and other phagocytic cells has historically been difficult. At Cell Guidance Systems, we have simplified the engineering of monocytes and other mononuclear phagocytes by using PODS, sub-micron scale sustained-release protein crystals that durably alter the cell's proteome. This simple technique is opening new research avenues and has the potential to enable cost-effective autologous immune cell therapies to treat a range of diseases.
In our immune system's fight against cancer, autologous immune cell therapy using CAR-T cells has transformed treatment options for patients with leukaemia and lymphoma but is not effective against solid tumors. Could monocytes and their derivatives, notably macrophages, succeed where CAR-T cells have failed? Here we look at the way cancers try to exert dominance over macrophages and the companies rising to the challenge of autologous macrophage therapy.
